Genetic determinants of malignancy in a mouse model for oligodendroglioma.

PubWeight™: 1.46‹?› | Rank: Top 5%

🔗 View Article (PMID 12670909)

Published in Cancer Res on April 01, 2003

Authors

William A Weiss1, Michael J Burns, Christopher Hackett, Ken Aldape, John R Hill, Hiroko Kuriyama, Nagato Kuriyama, Nadezhda Milshteyn, Tim Roberts, Michael F Wendland, Ron DePinho, Mark A Israel

Author Affiliations

1: Department of Neurology, University of California, San Francisco, California 94143-0663, USA. weiss@cglucsf.edu

Articles citing this

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10

The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10

Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05

Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95

Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res (2008) 1.75

Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell (2011) 1.67

Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66

mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol (2010) 1.65

Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61

Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28

CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer (2010) 1.26

Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22

In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol (2012) 1.21

Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells (2013) 1.17

Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15

Asymmetric cell division of stem and progenitor cells during homeostasis and cancer. Cell Mol Life Sci (2013) 1.11

Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. Neuro Oncol (2011) 1.08

Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk. Brain Pathol (2009) 0.97

Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia (2009) 0.96

Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proc Natl Acad Sci U S A (2014) 0.95

Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochim Biophys Acta (2013) 0.93

Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med (2009) 0.93

Origins and clinical implications of the brain tumor stem cell hypothesis. J Neurooncol (2009) 0.92

New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res (2011) 0.90

Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther (2014) 0.89

Developmental origins of brain tumors. Curr Opin Neurobiol (2012) 0.89

DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data. BMC Bioinformatics (2013) 0.88

Extrachromosomal driver mutations in glioblastoma and low-grade glioma. Nat Commun (2014) 0.88

Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87

Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One (2012) 0.86

Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol (2015) 0.85

NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis (2010) 0.81

What underlies the diversity of brain tumors? Cancer Metastasis Rev (2013) 0.81

Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol (2012) 0.80

Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells. PLoS One (2013) 0.80

Signals that regulate the oncogenic fate of neural stem cells and progenitors. Exp Neurol (2013) 0.79

Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78

Oligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes. J Neurosci (2013) 0.78

STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. Cancer Res (2015) 0.77

ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT. Transl Neurosci (2013) 0.77

In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cell Mol Life Sci (2014) 0.76

S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Res (2017) 0.75

Articles by these authors

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66

The transcriptional network for mesenchymal transformation of brain tumours. Nature (2009) 8.44

Heavy metal content of ayurvedic herbal medicine products. JAMA (2004) 7.33

Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57

Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54

Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09

A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57

The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30

miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med (2011) 2.24

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res (2009) 2.11

Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10

The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev Cell (2009) 2.04

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res (2002) 1.97

Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79

Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78

Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res (2008) 1.75

A role for Id2 in regulating photic entrainment of the mammalian circadian system. Curr Biol (2009) 1.70

T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol (2005) 1.69

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res (2006) 1.67

Microglial cells contribute to endogenous brain defenses after acute neonatal focal stroke. J Neurosci (2011) 1.64

Guidelines for management of idiopathic normal pressure hydrocephalus: second edition. Neurol Med Chir (Tokyo) (2012) 1.62

Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging (2002) 1.59

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56

Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A (2007) 1.54

Validation of in vivo magnetic resonance imaging blood-brain barrier permeability measurements by comparison with gold standard histology. Stroke (2011) 1.53

Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol (2006) 1.50

Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol (2008) 1.46

Id4 regulates neural progenitor proliferation and differentiation in vivo. Development (2004) 1.45

Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45

A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol (2012) 1.44

Positive cerebrospinal fluid cultures after normal cell counts are contaminants. J Emerg Med (2008) 1.42

Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol (2010) 1.40

MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40

Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. J Neurosci (2012) 1.39

Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol (2011) 1.38

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38

Macrophages are comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke. J Neurochem (2006) 1.36

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer (2005) 1.34

Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol (2013) 1.32

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30

Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab (2005) 1.29

Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2008) 1.25

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25

Profile of participants and genotype distributions of 108 polymorphisms in a cross-sectional study of associations of genotypes with lifestyle and clinical factors: a project in the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. J Epidemiol (2011) 1.22

Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem (2004) 1.17

Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology (2008) 1.17

Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: discrimination of viable from lysed cells. Magn Reson Med (2009) 1.17

Toward biocompatible nuclear hyperpolarization using signal amplification by reversible exchange: quantitative in situ spectroscopy and high-field imaging. Anal Chem (2014) 1.14

Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol (2006) 1.12

In vitro test of external Qigong. BMC Complement Altern Med (2004) 1.09

Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol (2002) 1.07

Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics (2011) 1.06

The use of global profiling in biomarker development for gliomas. Brain Pathol (2011) 1.06

Immunological and Psychological Benefits of Aromatherapy Massage. Evid Based Complement Alternat Med (2005) 1.04

Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol (2009) 1.03

Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res (2008) 1.03

Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03

Magnetic resonance imaging as a surrogate measure for histological sub-chronic endpoint in a neonatal rat stroke model. Brain Res (2005) 1.03

ID2 (inhibitor of DNA binding 2) is a rhythmically expressed transcriptional repressor required for circadian clock output in mouse liver. J Biol Chem (2009) 1.01

Neonatal cerebral hypoxia-ischemia impairs plasticity in rat visual cortex. J Neurosci (2010) 1.01

When do the aminotransferases rise after acute acetaminophen overdose? Clin Toxicol (Phila) (2010) 0.99

Assessment of arcuate fasciculus with diffusion-tensor tractography may predict the prognosis of aphasia in patients with left middle cerebral artery infarcts. Neuroradiology (2009) 0.99

Panax ginseng induces production of proinflammatory cytokines via toll-like receptor. J Interferon Cytokine Res (2004) 0.99

Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest (2012) 0.98

Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol (2008) 0.98

Genetic deletion of CD36 enhances injury after acute neonatal stroke. Ann Neurol (2012) 0.97

Anxiolytic effect of aromatherapy massage in patients with breast cancer. Evid Based Complement Alternat Med (2007) 0.97

Id2 is required for specification of dopaminergic neurons during adult olfactory neurogenesis. J Neurosci (2008) 0.96

A head holder for magnetic resonance imaging that allows the stereotaxic alignment of spontaneously occurring intracranial mouse tumors. J Neurosci Methods (2002) 0.96

IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. J Immunol (2007) 0.96

Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice. J Biol Chem (2010) 0.94

Exploratory Visual Analysis of statistical results from microarray experiments comparing high and low grade glioma. Cancer Inform (2007) 0.93

Aminoguanidine inhibits caspase-3 and calpain activation without affecting microglial activation following neonatal transient cerebral ischemia. J Neurochem (2006) 0.93

Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol (2002) 0.93

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol (2007) 0.92

p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. Stem Cells (2011) 0.91

Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. Cancer Res (2010) 0.91

Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice. Magn Reson Med (2009) 0.91

Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. J Neurooncol (2007) 0.90

Id2 is dispensable for Myc-induced epidermal neoplasia. Mol Cell Biol (2004) 0.90

New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging (2008) 0.88

Correlation of clinical neuromusculoskeletal and central somatosensory performance: variability in controls and patients with severe and mild focal hand dystonia. Neural Plast (2002) 0.88

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol (2005) 0.87

Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson's disease. Auton Neurosci (2011) 0.87

Evidence for lack of enhanced hedgehog target gene expression in common extracutaneous tumors. Cancer Res (2003) 0.87

The potential of contrast-enhanced magnetic resonance imaging for predicting left ventricular remodeling. J Magn Reson Imaging (2002) 0.86

Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int (2011) 0.86

Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg (2003) 0.86

Assessment of myocardial viability using standard extracellular and necrosis specific MR contrast media. Acad Radiol (2002) 0.86

The effect of aromatherapy massage on mild depression: a pilot study. Psychiatry Clin Neurosci (2005) 0.85

Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol (2010) 0.85

MR imaging of spatial extent of microvascular injury in reperfused ischemically injured rat myocardium: value of blood pool ultrasmall superparamagnetic particles of iron oxide. Radiology (2002) 0.85

Brain tumor stem cells. Curr Probl Cancer (2008) 0.85